A Single-arm, Multicenter Phase II Clinical Trial of TQ-B3525 Tablet in the Treatment of Relapsed / Refractory Mantle Cell Lymphoma (MCL)
Latest Information Update: 07 Jan 2022
At a glance
- Drugs TQ-B3525 (Primary)
- Indications Mantle-cell lymphoma
- Focus Therapeutic Use
- Sponsors Chia Tai Tianqing Pharmaceutical Group
Most Recent Events
- 10 Sep 2020 Status changed from not yet recruiting to recruiting.
- 27 May 2020 New trial record